-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FbNITCvaHpOSyJm+qhnySpxL1f/L2yPpqAYIuEp9uFKmVS5CWJA/OL1bvKIQWZ/W sViJEZHNjK7uUE2NV5C7Hw== 0001193125-08-239758.txt : 20081120 0001193125-08-239758.hdr.sgml : 20081120 20081120084443 ACCESSION NUMBER: 0001193125-08-239758 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20081120 DATE AS OF CHANGE: 20081120 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 081202488 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 425 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 20, 2008

 

 

OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Massachusetts   0-10824   04-2297484
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification Number)

 

1000 Winter Street, Suite 2200

Waltham, Massachusetts 02451

(Address of principal executive offices, including zip code)

 

(781) 398-2300

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


ITEM 8.01. OTHER EVENTS.

On November 20, 2008 Oscient Pharmaceuticals Corporation (the “Company”) announced the determination of the consideration issuable by the Company in its offer to exchange up to all of the $225,700,000 aggregate principal amount of its currently outstanding 3.50% Convertible Senior Notes due 2011 (the “Existing Notes”).

Holders that elect to participate in the exchange offer will receive, for each $1,000 principal amount of Existing Notes tendered, $400 principal amount of the Company’s 12.50% Convertible Guaranteed Senior Notes due 2011 (the “New Notes”) and 100 shares of the Company’s common stock. The New Notes will be convertible into shares of the Company’s common stock based on an initial conversion price of $1.10 per share (subject to adjustment).

A copy of the News Release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

 

ITEM  9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

99.1 News Release issued by the Company on November 20, 2008.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OSCIENT PHARMACEUTICALS CORPORATION
By:   /s/ Philippe M. Maitre
 

Name: Philippe M. Maitre

Title: Executive Vice President and Chief Financial Officer

Date: November 20, 2008

EX-99.1 2 dex991.htm NEWS RELEASE News Release

Exhibit 99.1

 

LOGO

Oscient Pharmaceuticals Contacts:

Christopher Taylor

781-398-2466

Sandra Schmidt Coombs

781-398-2310

For Immediate Release

Oscient Pharmaceuticals Announces Determination of the Consideration Issuable in its Exchange Offer

Waltham, Mass., November 20, 2008 – Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) (the “Company”) today announced the determination of the consideration issuable by the Company in its offer to exchange up to all of the $225,700,000 aggregate principal amount of its currently outstanding 3.50% Convertible Senior Notes due 2011 (the “Existing Notes”).

Holders that elect to participate in the exchange offer will receive, for each $1,000 principal amount of Existing Notes tendered, $400 principal amount of the Company’s 12.50% Convertible Guaranteed Senior Notes due 2011 (the “New Notes”) and 100 shares of the Company’s common stock. The New Notes will be convertible into shares of the Company’s common stock based on an initial conversion price of $1.10 per share (subject to adjustment).

The exchange offer will expire at 11:59 p.m., New York City time, on November 21, 2008, unless extended or terminated by the Company.

Lazard Capital Markets LLC and MTS Securities, LLC are serving as the dealer managers for the exchange offer. The registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet been declared effective. The exchange offer is conditioned upon the terms and conditions set forth in the offering materials referenced below, and on the registration statement being declared effective by the United States Securities and Exchange Commission.

A tender offer statement, registration statement (and the prospectus included therein), related letter of transmittal and other offering documents relating to the securities issuable in the exchange offer have been filed with the Securities and Exchange Commission but the registration statement has not yet become effective. These documents contain important information that should be read carefully before any decision is made with respect to the exchange offer. These securities may not be sold, nor may the exchange offer be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to exchange or sell or the solicitation of an offer to buy nor shall there be any offer, exchange or sale

-more-

Oscient Pharmaceuticals/ 1000 Winter Street Waltham MA 02451

t: 781.398.2300 f: 781.893.9535 www.oscient.com


Exchange Pricing

November 20, 2008

Page 2 of 2

 

of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

The prospectus, the related revised letter of transmittal and certain other offer documents are available to all holders of the 3.50% Convertible Senior Notes due 2011 free of charge from the information agent, The Altman Group, 1200 Wall Street West, 3rd Floor, Lyndhurst, NJ 07071, (866) 751-6316. The Tender Offer Statement (including the prospectus, the related letter of transmittal and all other offer documents filed with the Securities and Exchange Commission) is also be available for free at the Securities and Exchange Commission’s website at http://www.sec.gov.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA® (fenofibrate) capsules, a cardiovascular product and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a national sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists.

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.

###

GRAPHIC 3 g35317g62g91.jpg GRAPHIC begin 644 g35317g62g91.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`/9J**************************************** M*********************IWNJVMBVR5\RE=WEKUQZGL![G`JO%JKSGA%C'H> M2*T(69ERQ_2I**************************QO$>M-I=O%!;;#>W9*P^9] MV,`9>1O]E1R?P%H]Q4]%-=T MC0N[!5'4L<`5!!J-C7'?VSO_=692?RS5JHVFB1MK2H MI'8L!3D=)!E&5AZ@YIK31*Q5I4!'4%AFC[1!_P`]H_\`OH4]6##*D$'N*;YT M0;;YB;LXQN&:?4;3Q*Q5I4!'4%AQ3PP90RD$'H14:W5NZAEN(F!Z$.#FE^T0 M?\]H_P#OH4L5&/H!BNXIDD:2J5<9'Y&N0U*)UO#;&9HW M%RD0E7@HS@F&8>AW#8PZ,.M=!X>U-M8T2WO)4"3,"DJCHKJ2K8]L@U>N)X[6 MVEN)FVQQ(7<^@`R:X;PF'\;W5UK^L*9+2*8Q65DYS%&!@EBO1FY')]ZZ;5/" MVCZM9M;S644;8^2:%`CQGL58\BTFQF2-Y=/CN0U[&IQO7C`/MU_,5<.G>&?&^@AM,6VC=,-%) M'$%DMW'(!`P?PZ&NMSAX2WL\D)*W9G'\7` MS@^HKLY]`T>YMC;3:9:-$1C;Y*C'TP./PJGX7T!_#MM>6?G--`]TTD!=RS!" MJX!SZ$$5RWQ@L[8:+:7@@C%P;D(90H#%=K<9_`5W&CV=M8Z5;PVD$<,?EJ=J M*!DX')]37%_%VSM5\-QWBV\8N?M*+YRI\Q&UN">I'`K;M/"WAI=$@N;G2+/` MME>5VB']W))K3\.Z=%I6B06=O)O@4LT)Y^XS%E'/H"!7)>/_``U%K&M:5!9K M';7ET)R9U3!9D4,NXC\L]LU8\%^,)Y;D^&_$(,&JV_R(\G'G8[?[WOWZU:\9 M:5I]QJ6A236<+O+J2)(Q09==K'!]1P.OI74^2([8PVZI$`NU`!A5].!7/6W@ M?0+/24AETNUFFCB^>5DR7?'+9/J:Y3X6Z'I.K:->2W^G07+I<[5:5-Q`VCCF MN]T70[?0WO$LT2*VN)1*D2=$.T!OS(S6I17F;C[-X@OFFX^S>)()F]DD0J#^ M9K4T$&UO-+1^/LUY?63GT9F\Q?S"_K7<45QFNW,1U.:=FQ"D\#.W^Q;EI'/_ M`'TRH/\`:.*VO"5C/I_ARWCNDV7$I>>5/[K.Q;'X9Q5S6;1]0T2^LXSAY[=X MU^I4@5QOPFO572+S1Y1Y5W:7#,\3<,`<#I[$$'\*[[H,FO.O!L!U?XAZYX@A M&;)':&.3M(W`X_`9_$5WMQ/:-<)IUQM9[F-RL;KD.HP&'H?O#BO./%OA9_!L MH\4>&[AK58W`FMR?E`)QQZKG`(/X5Z):S'4]'AG*F,W5N&*_W=RY_K7GWPJN M/[+U+5O#U[^[NUEWJK<%L<-C]#]#7IM5X+VWN+FXMX9-\EL0)<=%)&<9]<3@E>N-V*Z&PDA$)M(Y1(]F%AEP,8;:#_(@_C61K0_ MXK/PW];G_P!%BH/&G@R+Q);+U++K5;[1=%U MB%XM6L=33S"5QO4*PR?0],^N3_+[2W M\,%VF/+F_P"N<@`&?P]:[2QO!>VXXYJ2>-Y$VH<9Z\X MK.AT"W$ZS7&)2A#*F,*"/ND^N.PZ`\XSS6M16'J?A/3M0U%=3C::QU!.EU:O ML<^S#D,/J*670+J\@-OJ&N7D\###QQJD6\>C,HSCZ$5IV5C:Z;:1VEE`D$$0 MPD:#`%4=;\/PZW+9S/=7-K-9NSQ26[A6!(QW!X]JJ77A3^U#&FLZK=7]M$P8 M6Y5(T?9PP=8(W55#`8S]W)[]3WID?A)H8DAB\1:TD:*%51<) M@`=!]RK^B:);Z%:RP037$YFF::22X?>[,<9)./:JVH>&4U'5H-2?5+^*:U), M"Q.@6/(P>-O.??-;,:E(U1G9RH`+-C+>YQ61J'A;3-1UNRUF1&CO+-@RO&0- MX'0-ZULU3U&P?4(/)6]N+52"&,!4%@?<@X_"LK0?!MIX;+#3;^^2)V#/"[HR ML1]5S^1KH:**:Z+(C(ZAE88*D9!'I6#)X<-JP-BV8E4JD3'YHU/5%)X9/]AN M/0BIK6&2!E.UXV4;1G(P/3GM[9;';%:T+EU.<'%2445AVUUJ-QX@N88Y5:UM MK@+(&QPAB!`&.<[SU],U-?WEU#KMG;PMNCEMY7>/2AG:+?(YP/KTJ/1=1NKBYNK:^&V4%9H0=O^J?H./0@C\JI76KWEMK\ MT7FD6<,L(D8H"L:,K9SCGJ%YZ#OQ6MK$MPNENUC.D5PY589&`*[B0!GVJAI6 MKW>H:N@E4P02VF]8&7#*ZMM;)Z]<@?3/>I-9U2XLKN!H3FW@96O.APC':/?C M[W'I5C6;V6TBM3&VR.6X6.:;&?*0@\_B0!D]-V:M6;AEDVW7VD!\!N/EX'&1 MU_\`KUEZ)?SW5S,L]SO"S3(B[DY"N0.`,]!U[U-<7[6VO^1<7(AM7M-Z;\`% MPV#@GOC'%7+7SI=,BWR,LSQ`ERHR"1UQC%4]$GN+G[3)+=M,(KB6%5(7&%;@ M\#KBI(KJ5O$=S:&0F)+6.14P.&+.#[]%%0O?2/J5_!/=_8EMPGD?*/G!7)?G M[W.1@>GO5W4IY(;)A"V)Y"(XNF=QXS@\<=?PJ/1;V2_TN*6<`7"9CG`[2*<- M^HS^-0Z'?FZMY%FN1+,+B90.,A%D95X'L!SWIE]?7%OK=O$)-UM+L0I'C>C$ MGE@1RI'&1TQ6Q1111128Q2T44F!Z48'I1@8QCBC`'848'I1@8Q@8HP,YQ1@> M@HP,8[4``#`&!0%`.0`*"`W4`X]:6D``Z#%&!G.*"`<9`..E&`>HH``Z"@*` M<@`48&
-----END PRIVACY-ENHANCED MESSAGE-----